Emerging insights into ferroptosis in cholangiocarcinoma (Review)

Zhao,Xiaoyue; Zhang,Miao; He,Jing; Li,Xin; Zhuang,Xuewei

doi:10.3892/ol.2024.14739

Emerging insights into ferroptosis in cholangiocarcinoma (Review)

Authors:
- Xiaoyue Zhao
- Miao Zhang
- Jing He
- Xin Li
- Xuewei Zhuang
View Affiliations

Affiliations: Second Clinical Medical College, Shandong University of Traditional Chinese Medicine, Jinan, Shandong 250002, P.R. China, Clinical Laboratory, Shandong Provincial Third Hospital, Shandong University, Jinan, Shandong 250002, P.R. China
Published online on: October 14, 2024 https://doi.org/10.3892/ol.2024.14739
Article Number: 606
Copyright: © Zhao et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Cholangiocarcinoma (CCA) is a malignant tumor that arises within the biliary system, which exhibits a progressively increasing incidence and a poor patient prognosis. A thorough understanding of the molecular pathogenesis that drives the progression of CCA is essential for the development of effective molecular target therapeutic approaches. Ferroptosis is driven by excessive iron accumulation and catalysis, lipid peroxidation and the failure of antioxidant defense systems. Key molecular targets of iron metabolism, lipid metabolism and antioxidant defense systems involve molecules such as transferrin receptor, ACSL4 and GPX4, respectively. Inhibitors of ferroptosis include ferrostatin‑1, liproxstatin‑1, vitamin E and coenzyme Q10. By contrast, compounds such as erastin, RSL3 and FIN56 have been identified as inducers of ferroptosis. Ferroptosis serves a notable role in the onset and progression of CCA. CCA cells exhibit high sensitivity to ferroptosis and aberrant iron metabolism in these cells increases oxidative stress and iron accumulation. The induction of ferroptosis markedly reduces the ability of CCA cells to proliferate and migrate. Certain ferroptosis agonists, such as RSL3 and erastin, cause lipid peroxide build up and GPX4 inhibition to induce ferroptosis in CCA cells. Current serological markers, such as CA‑199, have low specificity and cause difficulties in the diagnosis of CCA. However, novel techniques, such as non‑invasive liquid biopsy and assays for oxidative stress markers and double‑cortin‑like kinase 1, could improve diagnostic accuracy. CCA is primarily treated with surgery and chemotherapy. A close association between the progression of CCA with ferroptosis mechanisms and related regulatory pathways has been demonstrated. Therefore, it could be suggested that multi‑targeted therapeutic approaches, such as ferroptosis inducers, iron chelating agents and novel modulators such as YL‑939, may improve treatment efficacy. Iron death‑related genes, such as GPX4, that are highly expressed in CCA and are associated with a poor prognosis for patients may represent potential prognostic markers for CCA. The present review focused on molecular targets such as p53 and ACSL4, the process of targeted medications in combination with PDT in CCA and the pathways of lipid peroxidation, the Xc‑system and GSH‑GPX4 in ferroptosis. The present review thus offered novel perspectives to improve the current understanding of CCA.

View Figures

View References

1	Rizvi S and Gores GJ: Pathogenesis, diagnosis, and management of cholangiocarcinoma. Gastroenterology. 145:1215–1229. 2013. View Article : Google Scholar
2	Cardinale V: Classifications and misclassification in cholangiocarcinoma. Liver Int. 39:260–262. 2019. View Article : Google Scholar
3	Brindley PJ, Bachini M, Ilyas SI, Khan SA, Loukas A, Sirica AE, The BT, Wongkham S and Gores GJ: Cholangiocarcinoma. Nat Rev Dis Primers. 7:652021. View Article : Google Scholar
4	Sripa B, Suwannatrai AT, Sayasone S, Do DT, Khieu V and Yang Y: Current status of human liver fluke infections in the Greater Mekong Subregion. Acta Trop. 224:1061332021. View Article : Google Scholar
5	Qurashi M, Vithayathil M and Khan SA: Epidemiology of cholangiocarcinoma. Eur J Surg Oncol. 9:1070642023. View Article : Google Scholar
6	Kim R, Taylor D, Vonderheide RH and Gabrilovich DI: Ferroptosis of immune cells in the tumor microenvironment. Trends Pharmacol Sci. 44:542–552. 2023. View Article : Google Scholar
7	Xu Y, Xing Z, Suliman RAI, Liu Z and Tang F: Ferroptosis in liver cancer: A key role of post-translational modifications. Front Immunol. 15:13755892024. View Article : Google Scholar
8	Zhou TJ, Zhang MM, Liu DM, Huang LL, Yu HQ, Wang Y, Xing L and Jiang HL: Glutathione depletion and dihydroorotate dehydrogenase inhibition actuated ferroptosis-augment to surmount triple-negative breast cancer. Biomaterials. 305:1224472024. View Article : Google Scholar
9	Deng J, Lin X, Qin J, Li Q, Zhang Y, Zhang Q, Ji C, Shen S, Li Y, Zhang B and Lin N: SPTBN2 suppresses ferroptosis in NSCLC cells by facilitating SLC7A11 membrane trafficking and localization. Redox Biol. 70:1030392024. View Article : Google Scholar
10	Dixon SJ, Lemberg KM, Lamprecht MR, Skouta R, Zaitsev EM, Gleason CE, Patel DN, Bauer AJ, Cantley AM, Yang WS, et al: Ferroptosis: An iron-dependent form of nonapoptotic cell death. Cell. 149:1060–1072. 2012. View Article : Google Scholar
11	Nakamura T, Naguro I and Ichijo H: Iron homeostasis and iron-regulated ROS in cell death, senescence and human diseases. Biochim Biophys Acta Gen Subj. 1863:1398–1409. 2019. View Article : Google Scholar
12	D'Arcy MS: Cell death: A review of the major forms of apoptosis, necrosis and autophagy. Cell Biol Int. 43:582–592. 2019. View Article : Google Scholar
13	Fu C, Cao N, Zeng S, Zhu W, Fu X, Liu W and Fan S: Role of mitochondria in the regulation of ferroptosis and disease. Front Med (Lausanne). 10:13018222023. View Article : Google Scholar
14	Otasevic V, Vucetic M, Grigorov I, Martinovic V and Stancic A: Ferroptosis in different pathological contexts seen through the eyes of mitochondria. Oxid Med Cell Longev. 2021:55373302021. View Article : Google Scholar
15	Xie LH, Fefelova N, Pamarthi SH and Gwathmey JK: Molecular mechanisms of ferroptosis and relevance to cardiovascular disease. Cells. 11:27262022. View Article : Google Scholar
16	Liu J, Kang R and Tang D: Signaling pathways and defense mechanisms of ferroptosis. FEBS J. 289:7038–7050. 2022. View Article : Google Scholar
17	Liu T, Zhang L, Joo D and Sun SC: NF-κB signaling in inflammation. Signal Transduct Target Ther. 2:170232017. View Article : Google Scholar
18	Ahmad A and Ahsan H: Biomarkers of inflammation and oxidative stress in ophthalmic disorders. J Immunoassay Immunochem. 41:257–271. 2020. View Article : Google Scholar
19	Yang W, Wang Y, Zhang C, Huang Y, Yu J, Shi L, Zhang P, Yin Y, Li R and Tao K: Maresin1 protect against ferroptosis-induced liver injury through ROS inhibition and Nrf2/HO-1/GPX4 activation. Front Pharmacol. 13:8656892022. View Article : Google Scholar
20	Tanase DM, Gosav EM, Anton MI, Floria M, Isac PN, Hurjui LL, Tarniceriu CC, Costea CF, Ciocoiu M and Rezus C: Oxidative stress and NRF2/KEAP1/ARE pathway in diabetic kidney disease (DKD): New perspectives. Biomolecules. 12:12272022. View Article : Google Scholar
21	Ueda N and Takasawa K: Impact of inflammation on ferritin, hepcidin and the management of iron deficiency anemia in chronic kidney disease. Nutrients. 10:11732018. View Article : Google Scholar
22	Chen Y, Fang ZM, Yi X, Wei X and Jiang DS: The interaction between ferroptosis and inflammatory signaling pathways. Cell Death Dis. 14:2052023. View Article : Google Scholar
23	Schmitt A, Xu W, Bucher P, Grimm M, Konantz M, Horn H, Zapukhlyak M, Berning P, Brändle M, Jarboui MA, et al: Dimethyl fumarate induces ferroptosis and impairs NF-κ/STAT3 signaling in DLBCL. Blood. 138:871–884. 2021. View Article : Google Scholar
24	Yan N, Xu Z, Qu C and Zhang J: Dimethyl fumarate improves cognitive deficits in chronic cerebral hypoperfusion rats by alleviating inflammation, oxidative stress, and ferroptosis via NRF2/ARE/NF-κB signal pathway. Int Immunopharmacol. 98:1078442021. View Article : Google Scholar
25	Zhao C, Xiao C, Feng S and Bai J: Artemisitene alters LPS-induced oxidative stress, inflammation and ferroptosis in liver through Nrf2/HO-1 and NF-kB pathway. Front Pharmacol. 14:11775422023. View Article : Google Scholar
26	Yeung YT, Aziz F, Guerrero-Castilla A and Arguelles S: Signaling pathways in inflammation and anti-inflammatory therapies. Curr Pharm Des. 24:1449–1484. 2018. View Article : Google Scholar
27	Xu X, Mao C, Zhang C, Zhang M, Gong J and Wang X: Salvianolic Acid B inhibits ferroptosis and apoptosis during myocardial ischemia/reperfusion injury via decreasing the ubiquitin-proteasome degradation of GPX4 and the ROS-JNK/MAPK pathways. Molecules. 28:41172023. View Article : Google Scholar
28	Lu JS, Wang JH, Han K and Li N: Nicorandil regulates ferroptosis and mitigates septic cardiomyopathy via TLR4/SLC7A11 signaling pathway. Inflammation. 47:975–988. 2024. View Article : Google Scholar
29	Zhu K, Zhu X, Sun S, Yang W, Liu S, Tang Z, Zhang R, Li J, Shen T and Hei M: Inhibition of TLR4 prevents hippocampal hypoxic-ischemic injury by regulating ferroptosis in neonatal rats. Exp Neurol. 345:1138282021. View Article : Google Scholar
30	Cardoso-Pires C and Vieira HLA: Carbon monoxide and mitochondria: Cell energy and fate control. Biochim Biophys Acta Mol Basis Dis. 1870:1674462024. View Article : Google Scholar
31	Du L, Guo C, Zeng S, Yu K, Liu M and Li Y: Sirt6 overexpression relieves ferroptosis and delays the progression of diabetic nephropathy via Nrf2/GPX4 pathway. Ren Fail. 46:23777852024. View Article : Google Scholar
32	Sun K, Zhi Y, Ren W, Li S, Zhou X, Gao L and Zhi K: The mitochondrial regulation in ferroptosis signaling pathway and its potential strategies for cancer. Biomed Pharmacother. 169:1158922023. View Article : Google Scholar
33	Murphy MP: How mitochondria produce reactive oxygen species. Biochem J. 417:1–13. 2009. View Article : Google Scholar
34	Su D, Ding C, Wang R, Qiu J, Liu Y, Tao J, Luo W, Weng G, Yang G and Zhang T: E3 ubiquitin ligase RBCK1 confers ferroptosis resistance in pancreatic cancer by facilitating MFN2 degradation. Free Radic Biol Med. 221:136–154. 2024. View Article : Google Scholar
35	Zheng J and Conrad M: The metabolic underpinnings of ferroptosis. Cell Metab. 32:920–937. 2020. View Article : Google Scholar
36	Xiang Q, Wen J, Zhou Z, Dai Q, Huang Y, Yang N, Guo J, Zhang J, Ren F, Zhou X, et al: Effect of hydroxy-α-sanshool on lipid metabolism in liver and hepatocytes based on AMPK signaling pathway. Phytomedicine. 132:1558492024. View Article : Google Scholar
37	Copur S, Yildiz AB, Covic A and Kanbay M: Is there any robust evidence showing that SGLT2 inhibitor predisposes to cancer? Eur J Clin Invest. 54:e141312024. View Article : Google Scholar
38	Gao M, Yi J, Zhu J, Minikes AM, Monian P, Thompson CB and Jiang X: Role of mitochondria in ferroptosis. Mol Cell. 73:354–363. e3532019. View Article : Google Scholar
39	Qi Y, Zheng J, Zi Y, Song W, Chen X, Cao S, Zhou Q, Fu H and Hu X: Loureirin C improves mitochondrial function by promoting NRF2 nuclear translocation to attenuate oxidative damage caused by renal ischemia-reperfusion injury. Int Immunopharmacol. 138:1125962024. View Article : Google Scholar
40	Zhang T, Jing M, Fei L, Zhang Z, Yi P, Sun Y and Wang Y: Tetramethylpyrazine nitrone delays the aging process of C. elegans by improving mitochondrial function through the AMPK/mTORC1 signaling pathway. Biochem Biophys Res Commun. 723:1502202024. View Article : Google Scholar
41	Lane DJR, Metselaar B, Greenough M, Bush AI and Ayton SJ: Ferroptosis and NRF2: An emerging battlefield in the neurodegeneration of Alzheimer's disease. Essays Biochem. 65:925–940. 2021. View Article : Google Scholar
42	Zhang JY, Meng X, Zhu XL, Peng SR, Li HB, Mo HZ and Hu LB: Thymol induces fenton-reaction-dependent ferroptosis in vibrio parahemolyticus. J Agric Food Chem. 72:14337–14348. 2024. View Article : Google Scholar
43	Torti SV and Torti FM: Iron and cancer: More ore to be mined. Nat Rev Cancer. 13:342–355. 2013. View Article : Google Scholar
44	Zhang C: Essential functions of iron-requiring proteins in DNA replication, repair and cell cycle control. Protein Cell. 5:750–760. 2014. View Article : Google Scholar
45	Koppenol WH and Hider RH: Iron and redox cycling. Do's and don'ts. Free Radic Biol Med. 133:3–10. 2019. View Article : Google Scholar
46	Xu L, Liu Y, Chen X, Zhong H and Wang Y: Ferroptosis in life: To be or not to be. Biomed Pharmacother. 159:1142412023. View Article : Google Scholar
47	Hassannia B, Vandenabeele P and Berghe TV: Targeting ferroptosis to iron out cancer. Cancer Cell. 35:830–849. 2019. View Article : Google Scholar
48	Fang X, Ardehali H, Min J and Wang F: The molecular and metabolic landscape of iron and ferroptosis in cardiovascular disease. Nat Rev Cardiol. 20:7–23. 2023. View Article : Google Scholar
49	Truman-Rosentsvit M, Berenbaum D, Spektor L, Cohen LA, Belizowsky-Moshe S, Lifshitz L, Ma J, Li W, Kesselman E, Abutbul-Ionita I, et al: Ferritin is secreted via 2 distinct nonclassical vesicular pathways. Blood. 131:342–352. 2018. View Article : Google Scholar
50	Rochette L, Dogon G, Rigal E, Zeller M, Cottin Y and Vergely C: Lipid peroxidation and iron metabolism: Two corner stones in the homeostasis control of ferroptosis. Int J Mol Sci. 24:4492022. View Article : Google Scholar
51	Chen X, Yu C, Kang R and Tang D: Iron metabolism in ferroptosis. Front Cell Dev Biol. 8:5902262020. View Article : Google Scholar
52	Yu X, Guo Q, Zhang H, Wang X, Han Y and Yang Z: Hypoxia-inducible factor-1alpha can reverse the Adriamycin resistance of breast cancer adjuvant chemotherapy by upregulating transferrin receptor and activating ferroptosis. FASEB J. 38:e238762024. View Article : Google Scholar
53	Sies H: Oxidative stress: A concept in redox biology and medicine. Redox Biol. 4:180–183. 2015. View Article : Google Scholar
54	Chen S, Li Q, Shi H, Li F, Duan Y and Guo Q: New insights into the role of mitochondrial dynamics in oxidative stress-induced diseases. Biomed Pharmacother. 178:1170842024. View Article : Google Scholar
55	Jomova K, Raptova R, Alomar SY, Alwasel SH, Nepovimova E, Kuca K and Valko M: Reactive oxygen species, toxicity, oxidative stress, and antioxidants: Chronic diseases and aging. Arch Toxicol. 97:2499–2574. 2023. View Article : Google Scholar
56	Galaris D, Barbouti A and Pantopoulos K: Iron homeostasis and oxidative stress: An intimate relationship. Biochim Biophys Acta Mol Cell Res. 1866:1185352019. View Article : Google Scholar
57	Carocci A, Catalano A, Sinicropi MS and Genchi G: Oxidative stress and neurodegeneration: The involvement of iron. Biometals. 31:715–735. 2018. View Article : Google Scholar
58	Boldyreva LV, Morozova MV, Saydakova SS and Kozhevnikova EN: Fat of the gut: Epithelial phospholipids in inflammatory bowel diseases. Int J Mol Sci. 22:116822021. View Article : Google Scholar
59	Feng H and Stockwell BR: Unsolved mysteries: How does lipid peroxidation cause ferroptosis? PLoS Biol. 16:e20062032018. View Article : Google Scholar
60	Liang D, Minikes AM and Jiang X: Ferroptosis at the intersection of lipid metabolism and cellular signaling. Mol Cell. 82:2215–2227. 2022. View Article : Google Scholar
61	Li FJ, Long HZ, Zhou ZW, Luo HY, Xu SG and Gao LC: System X(c) (−)/GSH/GPX4 axis: An important antioxidant system for the ferroptosis in drug-resistant solid tumor therapy. Front Pharmacol. 13:9102922022. View Article : Google Scholar
62	Hussain S, Gupta G, Shahwan M, Bansal P, Kaur H, Deorari M, Pant K, Ali H, Singh SK, Allam VS, et al: Non-coding RNA: A key regulator in the Glutathione-GPX4 pathway of ferroptosis. Noncoding RNA Res. 9:1222–1234. 2024. View Article : Google Scholar
63	Xie Y, Kang R, Klionsky DJ and Tang D: GPX4 in cell death, autophagy, and disease. Autophagy. 19:2621–2638. 2023. View Article : Google Scholar
64	Liu Y, Wan Y, Jiang Y, Zhang L and Cheng W: GPX4: The hub of lipid oxidation, ferroptosis, disease and treatment. Biochim Biophys Acta Rev Cancer. 1878:1888902023. View Article : Google Scholar
65	Liu Y, Lu S, Wu LL, Yang L, Yang L and Wang J: The diversified role of mitochondria in ferroptosis in cancer. Cell Death Dis. 14:5192023. View Article : Google Scholar
66	Jiang X, Stockwell BR and Conrad M: Ferroptosis: Mechanisms, biology and role in disease. Nat Rev Mol Cell Biol. 22:266–282. 2021. View Article : Google Scholar
67	Dodson M, Castro-Portuguez R and Zhang DD: NRF2 plays a critical role in mitigating lipid peroxidation and ferroptosis. Redox Biol. 23:1011072019. View Article : Google Scholar
68	Liu Y, Su Z, Tavana O and Gu W: Understanding the complexity of p53 in a new era of tumor suppression. Cancer Cell. 42:946–967. 2024. View Article : Google Scholar
69	Shin D, Lee J and Roh JL: Pioneering the future of cancer therapy: Deciphering the p53-ferroptosis nexus for precision medicine. Cancer Lett. 585:2166452024. View Article : Google Scholar
70	Hu H, Zhang G, Tian M, Yin Y, Bao Y, Guan X, Ding C and Yu S: Brucella rough RB51 infection activates P53-Slc7a11-Gpx4/GSH pathway to induce ferroptosis to attenuate the intracellular survival on macrophages. Vet Microbiol. 298:1102242024. View Article : Google Scholar
71	Liao W, Zhang R, Chen G, Zhu X, Wu W, Chen Z, Jiang C, Lin Z, Ma L and Yu H: Berberine synergises with ferroptosis inducer sensitizing NSCLC to ferroptosis in p53-dependent SLC7A11-GPX4 pathway. Biomed Pharmacother. 176:1168322024. View Article : Google Scholar
72	Fu R, You Y, Wang Y, Wang J, Lu Y, Gao R, Pang M, Yang P and Wang H: Sanggenol L induces ferroptosis in non-small cell lung cancer cells via regulating the miR-26a-1-3p/MDM2/p53 signaling pathway. Biochem Pharmacol. 226:1163452024. View Article : Google Scholar
73	Zeng C, Xiong D, Zhang K and Yao J: Shank-associated RH domain interactor signaling in tumorigenesis. Oncol Lett. 20:2579–2586. 2020. View Article : Google Scholar
74	Zeng C, Lin J, Zhang K, Ou H, Shen K, Liu Q, Wei Z, Dong X, Zeng X, Zeng L, et al: SHARPIN promotes cell proliferation of cholangiocarcinoma and inhibits ferroptosis via p53/SLC7A11/GPX4 signaling. Cancer Sci. 113:3766–3775. 2022. View Article : Google Scholar
75	Chu B, Kon N, Chen D, Li T, Liu T, Jiang L, Song S, Tavana O and Gu W: ALOX12 is required for p53-mediated tumour suppression through a distinct ferroptosis pathway. Nat Cell Biol. 21:579–591. 2019. View Article : Google Scholar
76	Ou Y, Wang SJ, Li D, Chu B and Gu W: Activation of SAT1 engages polyamine metabolism with p53-mediated ferroptotic responses. Proc Natl Acad Sci USA. 113:E6806–E6812. 2016. View Article : Google Scholar
77	Lu B, Christensen IT, Yu T, Wang C, Yan Q and Wang X: SUMOylation evoked by oxidative stress reduced lens epithelial cell antioxidant functions by increasing the stability and transcription of TP53INP1 in age-related cataracts. Oxid Med Cell Longev. 2019:78980692019. View Article : Google Scholar
78	Wang J, Yi H, Li J, Yang Y, Sun G, Xue Y and He L: P62-autophagic pathway degrades SLC7A11 to regulate ferroptosis in doxorubicin-induced cardiotoxicity. Life Sci. 356:1229812024. View Article : Google Scholar
79	Lin Z, Wu C, Song D, Zhu C, Wu B, Wang J and Xue Y: Sarmentosin alleviates doxorubicin-induced cardiotoxicity and ferroptosis via the p62-Keap1-Nrf2 pathway. Redox Rep. 29:23923292024. View Article : Google Scholar
80	Zhao Y, Lu J, Mao A, Zhang R and Guan S: Autophagy inhibition plays a protective role in ferroptosis induced by alcohol via the p62-Keap1-Nrf2 Pathway. J Agric Food Chem. 69:9671–9683. 2021. View Article : Google Scholar
81	Zhou Y, Yang Y, Yi L, Pan M, Tang W and Duan H: Propofol mitigates sepsis-induced brain injury by inhibiting ferroptosis via activation of the Nrf2/HO-1axis. Neurochem Res. 49:2131–2147. 2024. View Article : Google Scholar
82	Liu N, Wu WL, Wan XR, Wang J, Huang JN, Jiang YY, Sheng YC, Wu JC, Liang ZQ, Qin ZH and Wang Y: Regulation of FSP1 myristoylation by NADPH: A novel mechanism for ferroptosis inhibition. Redox Biol. 73:1031762024. View Article : Google Scholar
83	Dai E, Zhang W, Cong D, Kang R, Wang J and Tang D: AIFM2 blocks ferroptosis independent of ubiquinol metabolism. Biochem Biophys Res Commun. 523:966–971. 2020. View Article : Google Scholar
84	Guo J, Chen L and Ma M: Ginsenoside Rg1 suppresses ferroptosis of renal tubular epithelial cells in sepsis-induced acute kidney injury via the FSP1-CoQ(10)- NAD(P)H pathway. Curr Med Chem. 31:2119–2132. 2024. View Article : Google Scholar
85	Li D and Li Y: The interaction between ferroptosis and lipid metabolism in cancer. Signal Transduct Target Ther. 5:1082020. View Article : Google Scholar
86	Torti SV and Torti FM: Iron and cancer: 2020 vision. Cancer Res. 80:5435–5448. 2020. View Article : Google Scholar
87	Toshida K, Itoh S, Iseda N, Izumi T, Bekki Y, Yoshiya S, Toshima T, Iwasaki T, Oda Y and Yoshizumi T: The association of transferrin receptor with prognosis and biologic role in intrahepatic cholangiocarcinoma. Ann Surg Oncol. 23:10.1245/s10434–024-16065-3. 2024.
88	Vogt AS, Arsiwala T, Mohsen M, Vogel M, Manolova V and Bachmann MF: On iron metabolism and its regulation. Int J Mol Sci. 22:45912021. View Article : Google Scholar
89	Guo W, Zhang S, Chen Y, Zhang D, Yuan L, Cong H and Liu S: An important role of the hepcidin-ferroportin signaling in affecting tumor growth and metastasis. Acta Biochim Biophys Sin (Shanghai). 47:703–715. 2015. View Article : Google Scholar
90	Raggi C, Gammella E, Correnti M, Buratti P, Forti E, Andersen JB, Alpini G, Glaser S, Alvaro D, Invernizzi P, et al: Dysregulation of iron metabolism in cholangiocarcinoma stem-like cells. Sci Rep. 7:176672017. View Article : Google Scholar
91	Kong L, Liu Y, Li J, Wang Y, Ji P, Shi Q, Han M, Xu H and Li W and Li W: Ginsenoside Rg1 alleviates chronic inflammation-induced neuronal ferroptosis and cognitive impairments via regulation of AIM2-Nrf2 signaling pathway. J Ethnopharmacol. 330:1182052024. View Article : Google Scholar
92	Caligiuri A, Becatti M, Porro N, Borghi S, Marra F, Pastore M, Taddei N, Fiorillo C and Gentilini A: Oxidative stress and redox-dependent pathways in cholangiocarcinoma. Antioxidants (Basel). 13:282023. View Article : Google Scholar
93	Thanan R, Oikawa S, Yongvanit P, Hiraku Y, Ma N, Pinlaor S, Pairojkul C, Wongkham C, Sripa B, Khuntikeo N, et al: Inflammation-induced protein carbonylation contributes to poor prognosis for cholangiocarcinoma. Free Radic Biol Med. 52:1465–1472. 2012. View Article : Google Scholar
94	Nevi L, Di Matteo S, Carpino G, Zizzari IG, Samira S, Ambrosino V, Costantini D, Overi D, Giancotti A, Monti M, et al: DCLK1, a putative stem cell marker in human cholangiocarcinoma. Hepatology. 73:144–159. 2021. View Article : Google Scholar
95	Takahashi Y, Dungubat E, Kusano H, Ganbat D, Tomita Y, Odgerel S and Fukusato T: Application of immunohistochemistry in the pathological diagnosis of liver tumors. Int J Mol Sci. 22:57802021. View Article : Google Scholar
96	Voigtländer T, Metzger J, Husi H, Kirstein MM, Pejchinovski M, Latosinska A, Frantzi M, Mullen W, Book T, Mischak H and Manns MP: Bile and urine peptide marker profiles: Access keys to molecular pathways and biological processes in cholangiocarcinoma. J Biomed Sci. 27:132020. View Article : Google Scholar
97	Xin H, Zhang Y, Lai Q, Liao N, Zhang J, Liu Y, Chen Z, He P, He J, Liu J, et al: Automatic origin prediction of liver metastases via hierarchical artificial-intelligence system trained on multiphasic CT data: A retrospective, multicentre study. EClinicalMedicine. 69:1024642024. View Article : Google Scholar
98	Yang Q, Cai Q, Wen H, Mao Y, Ban X, Rong D and Zhang R: The CT and MRI features of primary intrahepatic lymphoepithelioma-like cholangiocarcinoma. AJR Am J Roentgenol. 216:393–402. 2021. View Article : Google Scholar
99	Sae-Fung A, Mutirangura A and Jitkaew S: Identification and validation of a novel ferroptosis -related gene signature for prognosis and potential therapeutic target prediction in cholangiocarcinoma. Front Immunol. 13:10512732022. View Article : Google Scholar
100	Bao F, Liu J, Chen H, Miao L, Xu Z and Zhang G: Diagnosis biomarkers of cholangiocarcinoma in human bile: An evidence-based study. Cancers (Basel). 14:39212022. View Article : Google Scholar
101	Lapitz A, Azkargorta M, Milkiewicz P, Olaizola P, Zhuravleva E, Grimsrud MM, Schramm C, Arbelaiz A, O'Rourke CJ, La Casta A, et al: Liquid biopsy-based protein biomarkers for risk prediction, early diagnosis, and prognostication of cholangiocarcinoma. J Hepatol. 79:93–108. 2023. View Article : Google Scholar
102	El-Deiry WS, Goldberg RM, Lenz HJ, Shields AF, Gibney GT, Tan AR, Brown J, Eisenberg B, Heath EI, Phuphanich S, et al: The current state of molecular testing in the treatment of patients with solid tumors, 2019. CA Cancer J Clin. 69:305–343. 2019. View Article : Google Scholar
103	Scott A, Wong P and Melstrom LG: Surgery and hepatic artery infusion therapy for intrahepatic cholangiocarcinoma. Surgery. 174:113–115. 2023. View Article : Google Scholar
104	Benson AB III, D'Angelica MI, Abrams TA, Are C, Bloomston PM, Chang DT, Clary BM, Covey AM, Ensminger WD, Iyer R, et al: Hepatobiliary cancers, version 2.2014. J Natl Compr Canc Netw. 12:1152–1182. 2014. View Article : Google Scholar
105	Moris D, Palta M, Kim C, Allen PJ, Morse MA and Lidsky ME: Advances in the treatment of intrahepatic cholangiocarcinoma: An overview of the current and future therapeutic landscape for clinicians. CA Cancer J Clin. 73:198–222. 2023. View Article : Google Scholar
106	Saito N, Hatanaka T, Nakano S, Hazama Y, Yoshida S, Hachisu Y, Tanaka Y, Yoshinaga T, Kashiwabara K, Kubo N, et al: A case of unresectable combined hepatocellular and cholangiocarcinoma treated with atezolizumab plus bevacizumab. Clin Case Rep. 10:e61292022. View Article : Google Scholar
107	Simon-Molas H, Sanchez-de-Diego C, Navarro-Sabate A, Castaño E, Ventura F, Bartrons R and Manzano A: The expression of TP53-induced glycolysis and apoptosis regulator (TIGAR) can be controlled by the antioxidant orchestrator NRF2 in human carcinoma cells. Int J Mol Sci. 23:19052022. View Article : Google Scholar
108	Toshida K, Itoh S, Iseda N, Izumi T, Yoshiya S, Toshima T, Ninomiya M, Iwasaki T, Oda Y and Yoshizumi T: Impact of TP53-induced glycolysis and apoptosis regulator on malignant activity and resistance to ferroptosis in intrahepatic cholangiocarcinoma. Cancer Sci. 115:170–183. 2024. View Article : Google Scholar
109	Shi Y, Gong M, Deng Z, Liu H, Chang Y, Yang Z and Cai L: Tirapazamine suppress osteosarcoma cells in part through SLC7A11 mediated ferroptosis. Biochem Biophys Res Commun. 567:118–124. 2021. View Article : Google Scholar
110	Cao JY and Dixon SJ: Mechanisms of ferroptosis. Cell Mol Life Sci. 73:2195–2209. 2016. View Article : Google Scholar
111	Johnstone TC, Suntharalingam K and Lippard SJ: The next generation of platinum drugs: Targeted Pt(II) agents, nanoparticle delivery, and Pt(IV) prodrugs. Chem Rev. 116:3436–3486. 2016. View Article : Google Scholar
112	Kontoghiorghes GJ: New iron metabolic pathways and chelation targeting strategies affecting the treatment of all types and stages of cancer. Int J Mol Sci. 23:139902022. View Article : Google Scholar
113	Chen X, Li J, Kang R, Klionsky DJ and Tang D: Ferroptosis: Machinery and regulation. Autophagy. 17:2054–2081. 2021. View Article : Google Scholar
114	Yang W, Mu B, You J, Tian C, Bin H, Xu Z, Zhang L, Ma R, Wu M, Zhang G, et al: Non-classical ferroptosis inhibition by a small molecule targeting PHB2. Nat Commun. 13:74732022. View Article : Google Scholar
115	Zhang C, Liu J, Xu D, Zhang T, Hu W and Feng Z: Gain-of-function mutant p53 in cancer progression and therapy. J Mol Cell Biol. 12:674–687. 2020. View Article : Google Scholar
116	Hanson RL and Batchelor E: Coordination of MAPK and p53 dynamics in the cellular responses to DNA damage and oxidative stress. Mol Syst Biol. 18:e114012022. View Article : Google Scholar
117	Zhang C, Liu X, Jin S, Chen Y and Guo R: Ferroptosis in cancer therapy: A novel approach to reversing drug resistance. Mol Cancer. 21:472022. View Article : Google Scholar
118	Lei S, Cao W, Zeng Z, Zhang Z, Jin B, Tian Q, Wu Y, Zhang T, Li D, Hu C, et al: JUND/linc00976 promotes cholangiocarcinoma progression and metastasis, inhibits ferroptosis by regulating the miR-3202/GPX4 axis. Cell Death Dis. 13:9672022. View Article : Google Scholar
119	Ma S, Ma Y, Qi F, Lei J, Chen F, Sun W, Wang D, Zhou S, Liu Z, Lu Z and Zhang D: HSDL2 knockdown promotes the progression of cholangiocarcinoma by inhibiting ferroptosis through the P53/SLC7A11 axis. World J Surg Oncol. 21:2932023. View Article : Google Scholar
120	Shi X, Yang J, Wang M, Xia L, Zhang L and Qiao S: Hsa_circ_0050900 affects ferroptosis in intrahepatic cholangiocarcinoma cells by targeting hsa-miR-605-3p to regulate SLC3A2. Oncol Lett. 27:22024. View Article : Google Scholar
121	Kaida T, Beppu T, Hayashi H, Imai K, Yamamura K, Okabe H, Matsumura K, Yoshii D, Komohara Y, Akahoshi S, et al: Inflammatory liver tumor caused by fasciola hepatica mimicking intrahepatic cholangiocarcinoma. Anticancer Res. 40:2795–2800. 2020. View Article : Google Scholar
122	Agostinis P, Berg K, Cengel KA, Foster TH, Girotti AW, Gollnick SO, Hahn SM, Hamblin MR, Juzeniene A, Kessel D, et al: Photodynamic therapy of cancer: An update. CA Cancer J Clin. 61:250–281. 2011. View Article : Google Scholar
123	Zhang ZJ, Huang YP, Li XX, Liu ZT, Liu K, Deng XF, Xiong L, Zou H and Wen Y: A novel ferroptosis-related 4-gene prognostic signature for cholangiocarcinoma and photodynamic therapy. Front Oncol. 11:7474452021. View Article : Google Scholar
124	Gonzalez-Carmona MA, Bolch M, Strassburg CP and Weismuller TJ: Editorial: Shining a light on cholangiocarcinoma-a new dawn for photodynamic therapy? Authors' reply. Aliment Pharmacol Ther. 49:953–954. 2019. View Article : Google Scholar
125	Du J, Wan Z, Wang C, Lu F, Wei M, Wang D and Hao Q: Designer exosomes for targeted and efficient ferroptosis induction in cancer via chemo-photodynamic therapy. Theranostics. 11:8185–8196. 2021. View Article : Google Scholar
126	Yan X, Li Z, Chen H, Yang F, Tian Q and Zhang Y: Photodynamic therapy inhibits cancer progression and induces ferroptosis and apoptosis by targeting P53/GPX4/SLC7A11 signaling pathways in cholangiocarcinoma. Photodiagnosis Photodyn Ther. 47:1041042024. View Article : Google Scholar
127	Huang YP, Wang YX, Zhou H, Liu ZT, Zhang ZJ, Xiong L, Zou H and Wen Y: Surufatinib combined with photodynamic therapy induces ferroptosis to inhibit cholangiocarcinoma in vitro and in tumor models. Front Pharmacol. 15:12882552024. View Article : Google Scholar
128	Ingle J and Basu S: Mitochondria targeted AIE probes for cancer phototherapy. ACS Omega. 8:8925–8935. 2023. View Article : Google Scholar
129	Kojima Y, Tanaka M, Sasaki M, Ozeki K, Shimura T, Kubota E and Kataoka H: Induction of ferroptosis by photodynamic therapy and enhancement of antitumor effect with ferroptosis inducers. J Gastroenterol. 59:81–94. 2024. View Article : Google Scholar
130	Wang P, Hu Z, Yu S, Su S, Wu R, Chen C, Ye Y, Wang H, Ye X, Zhou Z, et al: A novel protein encoded by circFOXP1 enhances ferroptosis and inhibits tumor recurrence in intrahepatic cholangiocarcinoma. Cancer Lett. 598:2170922024. View Article : Google Scholar
131	Zhang Z, Akuetteh PD, Lin L, Wu Y, Li Y, Huang W, Ni H, Lv H and Zhang Q: Development and validation of a ferroptosis-related model for three digestive tract tumors based on a pan-cancer analysis. Epigenomics. 13:1497–1514. 2021. View Article : Google Scholar
132	Sae-Fung A, Mutirangura A and Jitkaew S: Identification and validation of a novel ferroptosis-related gene signature for prognosis and potential therapeutic target prediction in cholangiocarcinoma. Front Immunol. 13:10512732022. View Article : Google Scholar
133	Yao X, Chen B, Wang M, Zhang S, He B, Shi Z, Deng T, Bao W, Wang Y, Chen G and Bo Z: Exploration and validation of a novel ferroptosis-related gene signature predicting the prognosis of intrahepatic cholangiocarcinoma. Acta Biochim Biophys Sin (Shanghai). 54:1376–1385. 2022.
134	Wang Z, Zhang Y, Chen Y, Liu S, Li C and Li X: Identification of a ferroptosis-related gene signature for predicting the prognosis of cholangiocarcinoma. Expert Rev Gastroenterol Hepatol. 16:181–191. 2022. View Article : Google Scholar
135	Liu S, Fan S, Wang Y, Chen R, Wang Z, Zhang Y, Jiang W, Chen Y, Xu X, Yu Y, et al: ACSL4 serves as a novel prognostic biomarker correlated with immune infiltration in Cholangiocarcinoma. BMC Cancer. 23:4442023. View Article : Google Scholar
136	Hori Y, Yoh T, Nishino H, Okura K, Kurimoto M, Takamatsu Y, Satoh M, Nishio T, Koyama Y, Ishii T, et al: Ferroptosis-related gene glutathione peroxidase 4 promotes reprogramming of glucose metabolism via Akt-mTOR axis in intrahepatic cholangiocarcinoma. Carcinogenesis. 45:119–130. 2023. View Article : Google Scholar
137	Xu L, Gao X, Xing J and Guo Z: Identification of a necroptosis-related gene signature as a novel prognostic biomarker of cholangiocarcinoma. Front Immunol. 14:11188162023. View Article : Google Scholar